Other authors, by using a representative panel of cancer cells of different origins (breast, lung, prostate, oesophageal, and colorectal cell lines) with known genetic background, highlighted that compensatory mechanisms and feedback between the PI3K/AKT and RAS/MEK/ERK pathways are cell line-specific and that oncogenic driver mutations have a decisive role. This evidence concerns the gene MAP2K7 and cancer.